|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
49,450,000 |
Market
Cap: |
1.30(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$25.5 - $46.6 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 623 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
119,323 |
119,323 |
201,796 |
291,198 |
Total Sell Value |
$3,656,226 |
$3,656,226 |
$6,836,738 |
$12,122,941 |
Total People Sold |
1 |
1 |
15 |
17 |
Total Sell Transactions |
3 |
3 |
36 |
59 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wicki Andreas |
Director |
|
2014-03-06 |
4 |
S |
$80.11 |
$176,244 |
I/I |
(2,200) |
1,667,307 |
|
- |
|
Wicki Andreas |
Director |
|
2014-03-05 |
4 |
S |
$80.16 |
$1,818,651 |
I/I |
(22,687) |
1,669,507 |
|
- |
|
Stack David M |
President and CEO |
|
2013-12-30 |
4 |
AS |
$55.84 |
$837,560 |
D/D |
(15,000) |
2,987 |
|
- |
|
Stack David M |
President and CEO |
|
2013-12-30 |
4 |
OE |
$1.61 |
$24,150 |
D/D |
15,000 |
17,987 |
|
- |
|
Longenecker John P Phd |
Director |
|
2013-12-30 |
4 |
AS |
$55.55 |
$138,875 |
D/D |
(2,500) |
0 |
|
- |
|
Longenecker John P Phd |
Director |
|
2013-12-30 |
4 |
OE |
$1.61 |
$4,025 |
D/D |
2,500 |
2,500 |
|
- |
|
Scibetta James S |
Chief Financial Officer |
|
2013-12-30 |
4 |
AS |
$55.55 |
$555,500 |
D/D |
(10,000) |
5,000 |
|
- |
|
Scibetta James S |
Chief Financial Officer |
|
2013-12-30 |
4 |
OE |
$1.61 |
$16,100 |
D/D |
10,000 |
15,000 |
|
- |
|
Stack David M |
President and CEO |
|
2013-11-18 |
4 |
A |
$0.00 |
$0 |
D/D |
414 |
2,987 |
|
- |
|
Patou Gary |
Chief Medical Officer |
|
2013-11-18 |
4 |
A |
$0.00 |
$0 |
I/I |
83 |
198 |
|
- |
|
Markvicka Taunia |
Vice President, Commercial |
|
2013-11-06 |
4 |
AS |
$50.60 |
$2,556,980 |
D/D |
(50,000) |
0 |
|
- |
|
Markvicka Taunia |
Vice President, Commercial |
|
2013-11-06 |
4 |
OE |
$10.81 |
$540,500 |
D/D |
50,000 |
50,000 |
|
- |
|
Patou Gary |
Chief Medical Officer |
|
2013-10-01 |
4 |
AS |
$48.92 |
$978,400 |
D/D |
(20,000) |
0 |
|
- |
|
Patou Gary |
Chief Medical Officer |
|
2013-10-01 |
4 |
OE |
$1.61 |
$32,200 |
D/D |
20,000 |
20,000 |
|
- |
|
Scibetta James S |
Chief Financial Officer |
|
2013-09-30 |
4 |
AS |
$46.74 |
$467,400 |
D/D |
(10,000) |
5,000 |
|
- |
|
Scibetta James S |
Chief Financial Officer |
|
2013-09-30 |
4 |
OE |
$1.61 |
$16,100 |
D/D |
10,000 |
15,000 |
|
- |
|
Stack David M |
President and CEO |
|
2013-09-30 |
4 |
AS |
$47.01 |
$705,741 |
D/D |
(15,000) |
2,573 |
|
- |
|
Stack David M |
President and CEO |
|
2013-09-30 |
4 |
OE |
$1.61 |
$24,150 |
D/D |
15,000 |
17,573 |
|
- |
|
Longenecker John P Phd |
Director |
|
2013-09-30 |
4 |
AS |
$46.74 |
$116,850 |
D/D |
(2,500) |
0 |
|
- |
|
Longenecker John P Phd |
Director |
|
2013-09-30 |
4 |
OE |
$1.61 |
$4,025 |
D/D |
2,500 |
2,500 |
|
- |
|
Markvicka Taunia |
Vice President, Commercial |
|
2013-09-25 |
4 |
AS |
$47.00 |
$470,000 |
D/D |
(10,000) |
0 |
|
- |
|
Markvicka Taunia |
Vice President, Commercial |
|
2013-09-25 |
4 |
OE |
$5.49 |
$54,900 |
D/D |
10,000 |
10,000 |
|
- |
|
Kronenfeld Mark A. |
Director |
|
2013-09-11 |
4 |
B |
$37.01 |
$37,010 |
D/D |
1,000 |
1,000 |
2.39 |
- |
|
Wicki Andreas |
Director |
|
2013-09-11 |
4 |
S |
$37.25 |
$662,417 |
I/I |
(17,783) |
1,692,194 |
|
- |
|
Wicki Andreas |
Director |
|
2013-09-11 |
4 |
OE |
$2.69 |
$662,390 |
I/I |
79,033 |
1,707,291 |
|
- |
|
253 Records found
|
|
Page 3 of 11 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|